A treat-to-target approach for gout confers renoprotective effect in patients with chronic kidney disease stage 3-Reference-Cited by-同舟云学术

A treat-to-target approach for gout confers renoprotective effect in patients with chronic kidney disease stage 3

Published:2020-01-25 Issue:7 Volume:40 Page:1081-1087
ISSN:0172-8172
Container-title:Rheumatology International
language:en
Short-container-title:Rheumatol Int

Author:

Novella-Navarro Marta^ORCID,Cabrera-Alarcon Jose Luis^ORCID,Diaz-Torne Cesar^ORCID,Aramburu-Muñoz Francisco,Janta Iustina,Ortega de la O Maria Carmen,Prada-Ojeda Alejandro,Sala-Icardo Luis^ORCID,Urruticoechea-Arana Ana^ORCID,García de la Peña Lefebvre Paloma^ORCID,Calvo-Aranda Enrique^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Immunology,Immunology and Allergy,Rheumatology

Link

http://link.springer.com/content/pdf/10.1007/s00296-020-04517-4.pdf

Reference26 articles.

1. Kuo CF, Grainge MJ, Zhang W, Doherty M (2015) Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol 11:649–662

2. Li L, Yang C, Zhao Y, Zeng X, Liu F, Fu P (2014) Is hyperuricemia independent risk factor for new-onset chronic kidney disease? A systematic review and meta-analysis based on observational cohort studies. BMC Nephrol 15:122

3. Corry DB, Eslami P, Yamamoto K, Nyby MD, Makino H, Tuck ML (2008) Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens 26:269–275

4. Bove M, Cicero AFG, Borghi C (2017) The effect of xanthine oxidase inhibitors on blood pressure and renal function. Curr Hypertens Rep 19:95

5. Zeng XX, Tang Y, Hu K, Zhou X, Wang J, Zhu L et al (2018) Efficacy of febuxostat in hyperuricemic patients with mild to moderate chronic kidney disease: a meta-analysis of randomized clinical trials: a PRISMA-compliant article. Medicine 97:e0161

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prediction of renal and cardiometabolic outcomes in gout during urate‐lowering therapy by sonography;International Journal of Rheumatic Diseases;2023-10-02

2. Real-life results of urate-driven pharmacotherapy with three urate lowering drugs in gout: allopurinol, febuxostat and benzbromarone;Exploration of Musculoskeletal Diseases;2023-08-30

3. Chronic kidney disease: Which role for xanthine oxidoreductase activity and products?;Pharmacological Research;2022-10

4. Febuxostat Therapy for Patients with Gout and Stage 2–4 CKD: a Retrospective Study;Rheumatology and Therapy;2022-09-03

5. Gout Screening Identifies a Large Cardiovascular Population at Increased Risk of Mortality;JCR: Journal of Clinical Rheumatology;2022-07-30